title: Rivaroxaban versus enoxaparin after total knee arthroplasty.
authors.forename: Antonio
authors.initials: A
authors.lastname: Gómez-Outes
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Suárez-Gea
authors.forename: Antonio
authors.initials: A
authors.lastname: Blázquez-Pérez
authors.forename: Carmen
authors.initials: C
authors.lastname: Pozo-Hernández
authors.forename: Emilio
authors.initials: E
authors.lastname: Vargas-Castrillón
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D017984:Enoxaparin / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D009025:Morpholines / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012307:Risk Factors; D000069552:Rivaroxaban; D012449:Safety; D013876:Thiophenes / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban